Epilepsy is the most usual neurological problem in children worldwide, and the longer the seizure lasts during epilepsy, the more difficult it is to terminate, and the greater the risk of developing it. One of the drugs used to treat this disease is Vimpat (lacosamide) which has low drug interaction; therefore, it is suitable for monotherapy and polytherapy (multidrug therapy) in children. The present study is a systematic review, conducted by searching the databases of Elsevier, PubMed, Springer, and Wiley and with the keywords of status epilepticus, children, lacosamide, seizures, efficacy, and tolerability; studies that were performed between 2011-2019 were reviewed. Out of a total of 763 articles, 17 articles were finally selected for further review, based on the inclusion and exclusion criteria. The results showed that the use of lacosamide was associated with improved physical conditions and reduced seizures in children and its therapeutic role in pediatrics was significant. However, to better understand the role of this drug and its safe and appropriate dose in children, it is necessary to conduct further studies in this field.